Results 241 to 250 of about 3,237,112 (331)

Development of arrival-time diagnostic tool for X-ray pump-probe experiments at Shanghai Soft X-ray Free Electron Laser. [PDF]

J Synchrotron Radiat
Qiao Z, Fan J, Gao Z, Nie Y, Wen P, Wang X, Yan K, Ren H, Wang B, Jiang J, Shen Y, Zhang Y, Zhu W, Shu G, Xue C, Guo Z, Liu Z, Yang H, Qi Z, Zhang K, Liu T, Wang Z, Feng C, Tong Y, Liu Z, Jiang H.   +25 more
europepmc   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

MP-483498-005 TIMING, PREVALENCE, AND IMPACT OF EARLY RECURRENCE OF ATRIAL TACHYARRHYTHMIAS AFTER PULSED FIELD ABLATION: SECONDARY ANALYSIS OF PULSED AF [PDF]

Lucas V.A. Boersma, Andrea Natale, David E. Haines, David B. De Lurgio, Nitesh Sood, Francis E. Marchlinski, Hugh Calkins, Robert Hoyt, Prashanthan Sanders, JAMES W. IRWIN, Douglas L. Packer, Suneet Mittal, Sarfraz Durrani, Luigi Di Biase, Robert Sangrigoli, Hiroshi Tada, Tetsuo Sasano, Hirofumi Tomita, Teiichi Yamane, Oussama M. Wazni, Karl‐Heinz Kück, Jeffrey Cerkvenik, Kelly A. van Bragt, B G S Abeln, Atul Verma   +24 more
openalex   +1 more source

Uniform Time [PDF]

Science, 1880
openaire   +3 more sources

Considerations for Estimating Causal Effects of Informatively Timed Treatments. [PDF]

Epidemiology
Oganisian A.
europepmc   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Device and Circuit Co-Optimization of Split-Controlled Flip-Flops Against Aging Towards Low-Voltage Applications. [PDF]

Micromachines (Basel)
Zhao Y, Tan J, Chen L, Zhu H, Sun Q.
europepmc   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

Hypothalamic deiodinase type-3 establishes the period of circannual interval timing in mammals. [PDF]

Elife
Stewart C, Liddle TA, Tolla E, Lewis JE, Marshall C, Evans NP, Morgan PJ, Ebling FJP, Stevenson TJ.   +8 more
europepmc   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source